Representative EV-based candidate biomarkers in MASLD, with the design and stage of validation stated for each.
| Candidate marker | Compartment | Reported role | Design and stage of validation |
|---|---|---|---|
| Circulating miR-122, miR-34a, miR-192 | Serum or plasma, not vesicle-restricted | Associated with histological severity and hepatocyte ballooning | Cross-sectional, multiple independent cohorts; not EV-specific |
| Vesicular liver microRNA and EV proteome | Plasma, experimental model | Discriminated fatty liver disease from control | Murine discovery study; not validated in humans |
| Fibulin-3 | Serum EV proteome | Correlated with fibrosis progression; predicted liver-related events | Prospective outcome cohort; single cohort, external validation outstanding |
| EV concentration and size distribution | Plasma, total | Staging and identification of severe steatosis within machine-learning models | Single-cohort model development; cited from secondary literature |
| EpCAM-positive, CD133-positive EVs | Serum | Distinguished steatohepatitis from simple steatosis | Cross-sectional, biopsy-anchored; cited from secondary literature |
| GLUT1-positive hepatogenic exosomes | Plasma | Elevated in MASH; proposed for staging | Cross-sectional, biopsy-anchored; cited from secondary literature |
| ASGR1-positive vesicular miR-122, miR-192, miR-128-3p | Plasma, liver-specific vesicles | Tracked disease severity | Cross-sectional, biopsy-anchored; cited from secondary literature |
| Urinary EV lipidomic panel | Urine | Discriminated MASH from simple steatosis (AUC approximately 92%) | Single-cohort discovery with machine learning; overfitting not excluded |
ASGR1: asialoglycoprotein receptor 1; AUC: area under the receiver operating characteristic curve.
During the preparation of this work, the author(s) used Grammarly to correct grammatical and language errors. After utilizing the tool, the author(s) reviewed and edited the content as necessary.
MH: Conceptualization, Investigation, Validation, Supervision, Writing—original draft, Writing—review & editing. SF, KS & AS: Investigation, Validation, Writing—original draft, Writing—review & editing. All authors read and approved the submitted version.
The authors declare that they have no competing interests. Dr Khadija Shakoor and Dr Abdul Shakoor share a common surname; they are not related and the shared surname is coincidental. This relationship had no bearing upon the design, conduct or reporting of this review, and the authors declare that it gives rise to no competing interest.
Not applicable.
Not applicable.
Not applicable.
All data discussed in this review are available in the cited published sources.
Not applicable. This work received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
© The Author(s) 2026.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.